Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 Biomarker disease BEFREE We discuss the interplay between ERBB/SRC signaling, and polycystins and their depending signaling, with emphasis on thes changes that affect cell proliferation in cyst expansion, as well as the inflammation-associated fibrogenesis, which characterizes progressive disease. 31830556 2020
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE NSCLC patients harboring EGFR T790 M mutations who experienced progressive disease after first EGFR-TKI treatment and started osimertinib treatment between April 2016 and August 2018 were retrospectively screened. 31183631 2020
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 AlteredExpression disease BEFREE Immunohistochemistry analysis revealed that metastatic neck tumor with the clinical complete response to nivolumab showed higher PD-L1 expression with higher CD8+ TIL density, while primary lesion with progressive disease showed lower PD-L1 expression with lower CD8+ TIL density. 31300273 2020
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker disease BEFREE A retrospective analysis of UC patients progressing to frontline or later-line anti-PD-1/PD-L1 therapy in 10 European institutions was conducted between March 2013 and September 2017. 31699525 2020
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE Among the six cases with liver metastasis, KRAS mutation disappeared in the duration of stable disease or a partial response, and reappeared at the time of progressive disease. 31746520 2020
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 AlteredExpression disease BEFREE The elevation of PD-L1 expression on TC after neoadjuvant chemotherapy was more frequently observed in patients achieving stable disease or progressive disease than in patients achieving partial response (P=0.026). 31145232 2020
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.100 AlteredExpression disease BEFREE With a median follow-up of 18 months, 2 (33%) with biallelic TP53 inactivation died of progressive disease. 30183082 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.100 GeneticVariation disease BEFREE In patients with clinical benefit (progressive disease after 8 weeks), ctDNA testing revealed previously undetected mutations in RAS/BRAF (71%) and EGFR (47%), which often emerged polyclonally. 31350822 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE <b>Methods:</b> Patients with advanced NSCLC, known <i>EGFR</i> mutation and progressive disease on an EGFR TKI immediately prior to enrollment without intervening therapy were enrolled. 30915273 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.100 Biomarker disease BEFREE Patients who achieved stable disease (SD) or progressive disease (PD) received EC (epirubicin and cyclophosphamide) or HT (trastuzumab and paclitaxel) according to their HER2 status.The primary end point was the pCR rate. 30340871 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.100 AlteredExpression disease BEFREE IHC and irGEP revealed that pretreatment immune activity-including expression of immune checkpoint molecules-for CUP was similar to that for ICI-responsive malignancies (antitumor immune cell signatures: CUP versus PD, P = 0.002-0.067; CUP versus non-PD, P = 0.591-0.999), although VEGFA expression was associated with suppression of antitumor immunity in CUP (P = 0.008, false discovery rate = 0.010). 31519206 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.100 Biomarker disease BEFREE We report 2 patients with BRAF V600 mutant melanoma who were previously treated with anti-PD-1±anti-LAG-3 antibodies and were switched to BRAF/MEK-inhibitors because of progressive disease. 29939877 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 Biomarker disease BEFREE CNS progressive disease (PD) was defined as progression of CNS metastasis during EGFR-TKI treatment. 31179076 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 AlteredExpression disease BEFREE The median PD-L1 expression level among patients who experienced a response to pembrolizumab was significantly higher than among patients with stable or progressive disease (90% versus 75%, P < 0.001). 31435660 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE Adult patients (age > or = 18 years), with non squamous EGFR mutation, treated with first line palliative therapy, with non progressive disease post 4-6 cycles of pemetrexed-carboplatin were randomized. 31695838 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE In patients with clinical benefit (progressive disease after 8 weeks), ctDNA testing revealed previously undetected mutations in RAS/BRAF (71%) and EGFR (47%), which often emerged polyclonally. 31350822 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker disease BEFREE PD-1/PD-L1 inhibitor treatment is more effective for advanced non-small cell lung cancer patients in a real-world setting than in clinical trials; PD-1/PD-L1 inhibitor treatment is more effective for people who are over 70 than for people who are under 70. 30862891 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 AlteredExpression disease BEFREE To stratify patients, incorporation of histopathologic characteristics (percentage of extracellular mucin) and PD-L1 expression at the invasive front were used to generate a composite score, the CPM (composite PD-L1 and mucin) score, which discriminated patients who exhibited clinical benefit (complete, partial, or stable disease) from those patients with progressive disease. 31439614 2019
Entrez Id: 7422
Gene Symbol: VEGFA
VEGFA
0.100 Biomarker disease BEFREE Numerous agents target VEGF-mediated signaling, yet resistance and progressive disease still persists. 30572736 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE Chemotherapy naïve, advanced NSCLC patients with EGFR -sensitizing mutation received afatinib 40 mg/body until progressive disease (PD). 31027689 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE Blood samples were collected at baseline and every treatment cycle and analyzed for 31 RAS, RAF, and EGFR mutations until progressive disease or censoring using droplet digital PCR. 30459076 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 AlteredExpression disease BEFREE Notably, combination of TC PD-L1 expression with % CD8<sup>+</sup>PD-1<sup>+</sup>TIM-3<sup>-</sup>LAG-3<sup>-</sup> TIC identified three groups of patients for which irPFS and irORR were significantly different. 30670497 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE Here, we conducted a retrospective study to assess 375 patients whose initial biopsy indicated a TKI-sensitizing mutation (either EGFR 19del or L858R) and who developed PD after treatment with first-generation TKIs, and assayed for T790M status. 30927306 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 Biomarker disease BEFREE Continuation of EGFR TKI beyond progressive disease is confined to patients in asymptomatic stage when the EGFR addiction is still preserved in some subclones. 30864018 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 AlteredExpression disease BEFREE Moreover, comparison to six additional ICC patients who showed a partial response, stable disease, or progressive disease after PD-1 blockade treatment alone or in combination with chemotherapy demonstrated no difference in PD-L1 expression, TMB, MSI, and MMR status from those of the two CR patients, whereas the indel frequency was significantly higher in the CR patients. 31064408 2019